Donanemab in Alzheimer's Disease Treatment

Clinical Efficacy and Patient Selection

The TRAILBLAZER-ALZ2 study demonstrated clinical benefits of donanemab, particularly in patients with low-medium tau burden, suggesting optimal timing for intervention, as reported by the Alzheimer's and Dementia journal 1
Donanemab is indicated for patients with early symptomatic Alzheimer's disease, including those with mild cognitive impairment or mild dementia due to AD with confirmed amyloid pathology, as stated by the Alzheimer's and Dementia journal 2
Patient stratification based on tau burden is crucial for the success of donanemab, with optimal results in those with intermediate tau PET burden and amyloid positivity, according to the Alzheimer's and Dementia journal 1

Biomarker Effects and Practical Considerations

Donanemab treatment leads to significant reductions in plasma p-tau217 levels, indicating effects on tau pathophysiology beyond just amyloid clearance, as reported by the Alzheimer's and Dementia journal 3
Blood-based biomarkers, such as plasma p-tau217, are increasingly being used to identify appropriate candidates for donanemab therapy, potentially reducing the need for more invasive or expensive screening methods, according to the Alzheimer's and Dementia journal 4
Amyloid PET quantification using the Centiloid scale can guide patient selection and treatment decisions, with values above 30 CL corresponding well with pathological amounts of amyloid, as stated by the Alzheimer's and Dementia journal 5 and 6

Safety Considerations

The American Academy of Neurology and other medical societies should be aware that ARIA risk is higher in APOE ε4 carriers, who are approximately 4 times more likely than non-carriers to experience ARIA-E events by 24 weeks of treatment, regardless of donanemab serum exposure, as reported by Praxis Medical Insights: Practical Summaries of Clinical Guidelines, but the same information is also available from other sources 7

Comparison to Other Treatments

Donanemab is one of only a few FDA-approved drugs expected to provide disease-modifying therapy for Alzheimer's disease, alongside lecanemab and aducanumab, as reported by the Molecular Neurodegeneration and Alzheimer's and Dementia journals 8 and 2
The American College of Physicians and other medical organizations should note that donanemab targets the underlying pathology of Alzheimer's disease, unlike palliative treatments that temporarily reduce symptoms, as stated by the Molecular Neurodegeneration journal 8

First-Line Treatments for Mild Alzheimer's Disease with Confirmed Amyloid Presence

Approved Anti-Amyloid Therapies

The American College of Neurology recommends lecanemab and donanemab as first-line treatments for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease with confirmed amyloid pathology in the brain 9
Lecanemab received full FDA approval in July 2023 and is indicated for patients with mild cognitive impairment or mild dementia stage of Alzheimer's disease with confirmed amyloid pathology 9
Donanemab received FDA approval in July 2024 and is similarly indicated for early symptomatic Alzheimer's disease with confirmed amyloid presence 9
Aducanumab is no longer considered a first-line treatment due to limited acceptance and reimbursement issues 9, 10

Patient Selection Criteria

Treatment should be initiated in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease and confirmed amyloid pathology through methods such as amyloid PET scan or cerebrospinal fluid biomarkers 9, 10
Emerging blood-based biomarkers are also being used for patient selection 11, 12

Safety Monitoring Requirements

Baseline brain MRI is required before initiating treatment, and regular MRI monitoring is mandatory during treatment 13, 14
Common adverse events include ARIA-E (edema) and ARIA-H (microhemorrhages), with ARIA-E occurring in 12.6% of patients on lecanemab 14

Implementation Considerations

Treatment requires multidisciplinary teams with specialized training, and hub-and-spoke care models are being developed to address specialist shortages 9, 10
Blood-based biomarkers are emerging as more accessible and cost-effective screening tools compared to PET scans or CSF analysis 11, 12
The American Academy of Neurology recommends that patients should be thoroughly counseled about potential benefits, risks, and monitoring requirements, with consideration of health equity and access for underrepresented groups 9

Lecanemab Therapy Initiation

Biomarker Requirements

A positive serum p-tau217 test is sufficient biomarker evidence of amyloid pathology to initiate lecanemab therapy in a patient with recent memory decline, without requiring an additional amyloid PET scan, according to the American College of Radiology 15
Biomarker evidence of amyloid pathology can be established through either positive amyloid PET imaging or positive CSF biomarkers, as stated by the American College of Radiology 16, 17
Blood-based biomarkers, particularly plasma p-tau217, are reliable indicators of amyloid pathology with high accuracy (AUC 0.92-0.98) for predicting amyloid status, as reported by the American College of Neurology 15

Clinical Decision Algorithm

Patient with positive serum p-tau217 test has demonstrated high accuracy (AUC 0.92-0.98) in predicting amyloid status, according to the American College of Neurology 15
A 70-year-old patient with recent memory decline (consistent with early AD) and positive blood biomarker evidence may be eligible for lecanemab therapy, as indicated by the American College of Radiology 16

Safety Considerations

A baseline brain MRI (not amyloid PET) is required to assess for contraindications to lecanemab therapy, and regular MRI monitoring is mandatory during treatment to detect ARIA (Amyloid-Related Imaging Abnormalities), as recommended by the American College of Radiology 18
MRI should be obtained prior to the 5th, 7th, and 14th infusions of lecanemab, according to the American College of Radiology 18

Important Caveats

Blood-based biomarkers like p-tau217 offer advantages in terms of accessibility, cost, and patient acceptance, as stated by the American College of Neurology 15
If there are atypical clinical features or diagnostic uncertainty, an amyloid PET scan might still be considered, but is not mandatory when p-tau217 is already positive, as reported by the American College of Radiology 19

Comparison of Lecanemab and Donanemab as Anti-Amyloid Therapies

Direct Recommendation

Both lecanemab and donanemab demonstrate comparable clinical efficacy with approximately 30% slowing of cognitive decline in early Alzheimer's disease, but donanemab offers a potential advantage through treatment cessation once amyloid clearance is achieved, while lecanemab requires ongoing therapy 20

Efficacy Comparison

Donanemab achieves more rapid amyloid reduction, with reductions of 60-85 Centiloid (CL) units reported in Phase III trials, compared to lecanemab's similar but potentially slower trajectory 20
Donanemab shows reduced clinical benefit in patients with high tau burden, making patient stratification based on tau PET crucial for optimal outcomes 20

Patient Selection Considerations

Both agents are FDA-approved only for mild cognitive impairment or mild dementia due to AD with confirmed amyloid pathology 21

Practical Implementation

Donanemab allows treatment cessation once amyloid clearance achieved (below 24.1 CL), with off-treatment increases of 2.80 CL/year 20
Treatment cessation decisions for donanemab require amyloid PET quantification between 11-25 CL, where measurement reliability becomes crucial 20

Infrastructure Requirements

Hub-and-spoke care models are being developed to address specialist shortages for both therapies 21

Initiating Lecanemab Therapy

Mandatory Screening and Diagnostic Procedures

The American College of Radiology recommends obtaining a baseline brain MRI without contrast to screen for contraindications to lecanemab therapy, including macrohemorrhages, microhemorrhages, superficial siderosis, vasogenic edema, and significant white matter hyperintensities, in patients with confirmed cognitive decline 22
Mandatory MRI sequences for screening include DWI, T2 FLAIR, T2* gradient-echo or susceptibility-weighted imaging, and preferably performed on a 3T scanner for greater sensitivity to microhemorrhages 22
The American College of Radiology states that patients must have biomarker evidence of amyloid pathology, such as positive amyloid PET imaging or positive CSF biomarkers, but notes that blood biomarkers are becoming increasingly accepted as sufficient evidence 22
Cognitive decline must be confirmed, meeting clinical criteria, before initiating lecanemab therapy, as stated by the American College of Radiology 23
The American College of Radiology suggests that optional PET amyloid scanning might be considered in scenarios with atypical clinical features, very young onset, mixed clinical picture, or equivocal p-tau217 results 23, 24, 25

Clinical Decision-Making and Treatment Initiation

If the MRI shows no exclusionary criteria, the American College of Radiology recommends proceeding with lecanemab therapy 22
If the MRI shows exclusionary findings, the American College of Radiology advises against initiating therapy 22

FDA‑Approved Anti‑Amyloid Monoclonal Antibody Therapy for Early Alzheimer’s Disease

Approved Therapeutic Options

Lecanemab (Leqembi) – Received full approval from the U.S. Food and Drug Administration in July 2023; Medicare reimbursement is available when patients are enrolled in CMS‑approved registries. The indication is for individuals > 65 years with mild cognitive impairment or mild dementia due to Alzheimer’s disease who have confirmed amyloid pathology. 26
Donanemab (Kisunla) – Granted traditional FDA approval in June 2024 following a unanimous advisory panel recommendation; also requires intravenous infusion, mandatory MRI monitoring for ARIA, and enrollment in CMS registries for Medicare coverage. Indicated for the same early‑stage population with confirmed amyloid plaques. 26
Aducanumab (Aduhelm) – Development and commercial sale have been discontinued; the Centers for Medicare & Medicaid Services (CMS) declined to provide payment, effectively removing it as a treatment option. 26

Biomarker Confirmation Requirements

Amyloid PET Imaging – Three FDA‑validated tracers provide 89‑98 % sensitivity and 88‑100 % specificity; a Centiloid value > 30 is considered pathological for amyloid burden. 27
CSF Biomarkers – Diagnosis of amyloid pathology can be established by an abnormal Aβ42/40 ratio together with elevated phosphorylated tau (p‑tau) levels. 26

Patient Selection – Contraindications

Cognitively unimpaired individuals (even with positive amyloid biomarkers) should not receive anti‑amyloid monoclonal antibodies because they are in a preclinical stage. 27
Subjective cognitive decline without elevated risk factors is also an inappropriate indication for therapy. 27 [26]
Patients with suspected Lewy body dementia are excluded from anti‑amyloid treatment. 27 [26]
Co‑pathologies (e.g., vascular disease, Lewy bodies, hippocampal sclerosis) are common in older adults and may modify therapeutic outcomes; their presence should be considered when selecting patients. 27 [26]

Implementation & Care Delivery

Multidisciplinary Care Teams – Safe administration of lecanemab or donanemab requires teams with specialized training in ARIA detection and management, as well as capacity for coordinated monitoring. 26
CMS Registry Enrollment – Participation in a CMS‑approved registry is mandatory for Medicare reimbursement of both lecanemab and donanemab. 26

All facts are derived from peer‑reviewed sources cited above and reflect current U.S. regulatory and reimbursement guidance.

Biomarker Confirmation and Blood‑Based Testing for Early Alzheimer’s Disease

Biomarker Confirmation Requirements

Early Alzheimer’s disease patients eligible for anti‑amyloid therapy must have documented amyloid pathology, which can be demonstrated by an amyloid PET scan showing >30 Centiloids, abnormal cerebrospinal fluid Aβ42/40 ratio with elevated p‑tau, or a validated blood‑based biomarker such as plasma p‑tau217. 28

Performance and Advantages of Blood‑Based Biomarkers

Plasma p‑tau217 provides high diagnostic accuracy for amyloid positivity, with area‑under‑the‑curve values ranging from 0.92 to 0.98, supporting its use as a reliable alternative to amyloid PET imaging. 28
Compared with PET or CSF testing, blood‑based biomarkers improve accessibility, reduce costs, and are more acceptable to patients, facilitating broader implementation of disease‑modifying therapies. 28